Business securities lawsuit

REGENXBIO Securities Fraud Class Action

Analysis based on 29 articles · First reported Feb 20, 2026 · Last updated Apr 15, 2026

Sentiment

-20

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The lawsuit against REGENXBIO could lead to a decline in its stock price due to potential financial liabilities and loss of investor confidence. For the legal industry, specifically Rosen Law Firm, this event reinforces its position in securities class action litigation.

Biotechnology Legal Services

Event Summary

Rosen Law Firm has filed a class action lawsuit against REGENXBIO, Inc. on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026. The lawsuit alleges that REGENXBIO made false and misleading statements regarding the efficacy and safety of its gene therapy product candidate, RGX-111, for the treatment of Hurler syndrome. Investors are reminded of the April 14, 2026, lead plaintiff deadline to join the class action. The firm claims that REGENXBIO's positive assertions about RGX-111's trial success were misleading, causing damages to investors when the true details emerged.

Key Actions

100 Rosen Law Firm filed class action lawsuit REGENXBIO

90 REGENXBIO made false and misleading statements

Entities Involved

stock

REGENXBIO

REGENXBIO is facing a securities fraud class action lawsuit for allegedly making false and misleading statements regarding its gene therapy product candidate RGX-111. This could lead to significant financial penalties and reputational damage for REGENXBIO.

Importance 100 Sentiment -50

priv

Rosen Law Firm

Rosen Law Firm is initiating and representing investors in the class action lawsuit against REGENXBIO, aiming to secure compensation for affected shareholders. This event enhances Rosen Law Firm's profile in securities litigation.

Importance 80 Sentiment 50

priv

The Schall Law Firm

The Schall Law Firm is representing investors in a class action lawsuit against REGENXBIO, alleging securities fraud. The firm is actively encouraging affected shareholders to join the lawsuit.

Importance 70 Sentiment 20

priv

DJS Law Group

DJS Law Group is representing investors in a class action lawsuit against REGENXBIO, aiming to enhance investor return through legal action. This event positively impacts DJS Law Group's business as they specialize in securities class actions.

Importance 70 Sentiment 50

priv

The Gross Law Firm

The Gross Law Firm is representing shareholders in a class action lawsuit against REGENXBIO, seeking recovery for investors who incurred losses due to alleged false and misleading statements.

Importance 70 Sentiment 50

priv

Faruqi & Faruqi

Faruqi & Faruqi, a national securities law firm, is investigating potential claims against REGENXBIO and is encouraging investors to join a class action lawsuit. The firm is actively seeking lead plaintiffs for the case.

Importance 70 Sentiment 20

govactor

United States===U.S. Food and Drug Administration

The United States===U.S. Food and Drug Administration placed a clinical hold on REGENXBIO's RGX-111 product candidate due to safety concerns, directly impacting the company's product development and market standing.

Importance 60 Sentiment 0

+ 7 more entities View on Dashboard

Relationships

Phillip Kim related ↔ Rosen Law Firm

Laurence Rosen related ↔ Rosen Law Firm

REGENXBIO related ↔ Rosen Law Firm

REGENXBIO related ↔ The Schall Law Firm

REGENXBIO related ↔ DJS Law Group

REGENXBIO related ↔ The Gross Law Firm

James Wilson (lawyer) related ↔ Faruqi & Faruqi

REGENXBIO related ↔ Faruqi & Faruqi

REGENXBIO related ↔ United States===Food and Drug Administration

Faruqi & Faruqi related ↔ United States===Food and Drug Administration

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard